Evidence map›Paper›PMID 32200451›Full record

ArticleMolecular biology reports2020

TIMP1 intron 3 retention is a marker of colon cancer progression controlled by hnRNPA1.

Marion Flodrops, Gwendal Dujardin, Adeline Busson, Pascal Trouvé, Chandran Ka, Brigitte Simon, Danielle Arzur, Catherine Le Jossic-Corcos, Laurent Corcos

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Marion FlodropsUMR1078 INSERM, Université de Brest, Génétique Génomique Fonctionnelle et Biotechnologies, 22 avenue Camille Desmoulins, 29200, Brest, France.
Gwendal DujardinSir William Dunn School of Pathology, University of Oxford, Oxford, England.
Adeline BussonUMR1078 INSERM, Université de Brest, Génétique Génomique Fonctionnelle et Biotechnologies, 22 avenue Camille Desmoulins, 29200, Brest, France.
Pascal TrouvéUMR1078 INSERM, Université de Brest, Génétique Génomique Fonctionnelle et Biotechnologies, 22 avenue Camille Desmoulins, 29200, Brest, France.
Chandran KaUMR1078 INSERM, Université de Brest, Génétique Génomique Fonctionnelle et Biotechnologies, 22 avenue Camille Desmoulins, 29200, Brest, France.
Brigitte SimonUMR1078 INSERM, Université de Brest, Génétique Génomique Fonctionnelle et Biotechnologies, 22 avenue Camille Desmoulins, 29200, Brest, France.
Danielle ArzurUMR1078 INSERM, Université de Brest, Génétique Génomique Fonctionnelle et Biotechnologies, 22 avenue Camille Desmoulins, 29200, Brest, France.
Catherine Le Jossic-CorcosUMR1078 INSERM, Université de Brest, Génétique Génomique Fonctionnelle et Biotechnologies, 22 avenue Camille Desmoulins, 29200, Brest, France.
Laurent CorcosUMR1078 INSERM, Université de Brest, Génétique Génomique Fonctionnelle et Biotechnologies, 22 avenue Camille Desmoulins, 29200, Brest, France. laurent.corcos@univ-brest.fr.ORCID http://orcid.org/0000-0001-8019-2505
Inserm · FRUniversity of Oxford · GB

Funding

Ligue Contre le Cancer (FR) RPH18240NN
6 · The paper itself

Abstract

We previously reported a 40-transcripts signature marking the normal mucosa to colorectal adenocarcinoma transition. Eight of these mRNAs also showed splicing alterations, including a specific intron 3 retention in tissue metalloprotease inhibitor I (TIMP1), which decreased during the early steps of colorectal cancer progression. To decipher the mechanism of intron 3 retention/splicing, we first searched for putative RNA binding protein binding sites onto the TIMP1 sequence. We identified potential serine arginine rich splicing factor 1 (SRSF1) and heterogeneous nuclear RiboNucleoProtein A1 (hnRNPA1) binding sites at the end of intron 3 and the beginning of exon 4, respectively. RNA immunoprecipitation showed that hnRNPA1, but not SRSF1 could bind to the corresponding region in TIMP1 pre-mRNA in live cells. Furthermore, using a TIMP1-based ex vivo minigene approach, together with a plasmon resonance in vitro RNA binding assay, we confirmed that hnRNPA1 could indeed bind to wild type TIMP1 exon 4 pre-mRNA and control TMP1 intron 3 splicing, the interaction being abolished in presence of a mutant sequence that disrupted this site. These results indicated that hnRNPA1, upon binding to TIMP1 exon 4, was a positive regulator of intron 3 splicing. We propose that this TIMP1-intron 3 + transcript belongs to the class of nuclear transcripts with "detained" introns, an abundant molecular class, including in cancer.

Indexed as

Alternative SplicingBinding SitesBiomarkers, TumorColonic NeoplasmsExonsHCT116 CellsHeterogeneous Nuclear Ribonucleoprotein A1HumansIntronsProtein BindingRNA PrecursorsRNA SplicingSerine-Arginine Splicing FactorsTissue Inhibitor of Metalloproteinase-1Biomarkers, TumorHeterogeneous Nuclear Ribonucleoprotein A1hnRNPA1 protein, humanRNA PrecursorsSerine-Arginine Splicing FactorsSRSF1 protein, humanTIMP1 protein, humanTissue Inhibitor of Metalloproteinase-1Alternative pre-mRNA splicingBiomarkerColorectal cancerhnRNPA1TIMP1

Identifiers

PMID32200451
OpenAlexW3012684487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.